CDKN2A and breast carcinoma: ,64 Seminal proof of principle experiments, involving the genetic elimination of cells expressing the senescence marker p16Ink4a, has demonstrated an alleviation of age- and therapy-induced pathologies,5,6 including progression and metastasis in a PyMT-MMTV spontaneous mammary carcinoma model.37